Genomic grade index is associated with response to chemotherapy in patients with breast cancer

Journal of Clinical Oncology

Volumn 27, Issue 19, 2009, Pages 3185-3191

  Liedtke, Cornelia ^a   Hatzis, Christos ^a   Symmans, William Fraser ^a   Desmedt, Christine ^a   Haibe Kains, Benjamin ^a   Valero, Vicente ^a   Kuerer, Henry ^a   Hortobagyi, Gabriel N ^a   Piccart Gebhart, Martine ^a   Sotiriou, Christos ^a   Pusztai, Lajos ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION; GENETIC ASSOCIATION; GENOMIC GRADE INDEX; HUMAN; PARAMETER; PRIORITY JOURNAL; SCORING SYSTEM; TREATMENT RESPONSE; ADJUVANT THERAPY; AREA UNDER THE CURVE; BREAST TUMOR; DNA MICROARRAY; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; ROC CURVE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PACLITAXEL; RECEPTORS, ESTROGEN; ROC CURVE; TREATMENT OUTCOME;

EID: 67650327607     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.5934     Document Type: Article

References (22)

1. Rakha EA, El-Sayed ME, Lee AH, et al: Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 26:3153-3158, 2008
2. Trudeau ME, Pritchard KI, Chapman JA, et al: Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Res Trt 89:35-45, 2005
3. Fisher ER, Wang J, Bryant J, et al: Pathobiology of preoperative chemotherapy: Findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 95:681-695, 2002
4. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 20:3628-3636, 2002
5. Sotiriou C, Wirapati P, Loi S, et al: Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98:262-272, 2006
6. Loi S, Haibe-Kains B, Desmedt C, et al: Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239-1246, 2007
7. Mamounas EP, Fisher B: Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 28:389-399, 2001
8. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007
9. Chang J, Powles TJ, Allred DC, et al: Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 17:3058-3063, 1999
10. Ellis P, Smith I, Ashley S, et al: Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J Clin Oncol 16:107-114, 1998
11. Vincent-Salomon A, Rousseau A, Jouve M, et al: Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 40:1502-1508, 2004
12. Rouzier R, Pusztai L, Delaloge S, et al: Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol 23:8331-8339, 2005
13. Buzdar AU, Valero V, Ibrahim NK, et al: Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13:228-233, 2007
14. Viani GA, Afonso SL, Stefano EJ, et al: Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 7:153, 2007
15. Hess KR, Anderson K, Symmans WF, et al: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-4244, 2006
16. Pusztai L, Symmans FW, Hortobagyi GN: Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 12:73-85, 2005
17. Rouzier R, Perou CM, Symmans WF, et al: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685, 2005
18. Mazouni C, Peintinger F, Wan-Kau S, et al: Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol 25:2650-2655, 2007
19. Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105:97-102, 1957
20. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
21. Hess KR, Pusztai L, Buzdar AU, et al: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 78:105-118, 2003
22. Tordai A, Wang J, Andre F, et al: Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 10:1-9, 2008